The terms of the distribution agreement grant exclusive rights to MyungMoon for the sale, marketing, and distribution of ACell’s MicroMatrix and Cytal Wound Matrix devices in South Korea. MyungMoon will work with ACell to obtain local regulatory clearance.
“South Korea is one of the largest healthcare markets in the Asia Pacific, and this agreement will meet a growing unmet need for innovative wound management solutions in the country,” said Nino Pionati, ACell Vice President, International and Business Development. “We are excited about this partnership, and the opportunity to bring ACell’s regenerative products to the patients and clinicians of South Korea.”
“Our Cytal and MicroMatrix wound management devices facilitate remodeling of healthy, functional tissue in a range of complex and hard-to-heal wounds, said ACell CEO Patrick McBrayer. “This agreement expands access to these products even further across the globe, and continues ACell’s path towards becoming the global leader in complex wound care.”
“MyungMoon Bio is very fortunate to become a business partner of ACell, which is opening new horizons in regenerative medicine. MyungMoon Bio, equipped with solid organization and sales capacity in the South Korean market, will lay the groundwork for ACell to achieve early success in the Asian region”, said MyungMoon Bio President, Mr. Sha—Joung Chang.
Source: Company Press Release
